Emerging Role of Organ‐on‐a‐Chip Technologies in Quantitative Clinical Pharmacology Evaluation

Abstract

The recently enacted Prescription Drug User Fee Act (PDUFA) VI includes in its performance goals "enhancing regulatory science and expediting drug development". The key elements in "enhancing regulatory decision tools to support drug development and review" include "advancing model‐informed drug development (MIDD)". This paper describes (1) the FDA's Office of Clinical Pharmacology's continuing efforts in developing quantitative clinical pharmacology models (disease‐, drug‐ and clinical trial‐ models) to advance MIDD, (2) how emerging novel tools such as organ‐on‐a‐chip technologies or microphysiological systems can provide new insights into physiology and disease mechanisms, biomarker identification and evaluation, and elucidation of mechanisms of adverse drug reactions, and (3) how the single organ or linked organ microphysiological systems can provide critical system parameters for improved physiologically‐based pharmacokinetic and pharmacodynamic evaluations. Continuous public‐private partnerships are critical to advance this field and in the application of these new technologies in drug development and regulatory review.

This article is protected by copyright. All rights reserved.

http://bit.ly/2USxG3k